Article Text
Statistics from Altmetric.com
During the first summer wave of the 2009 pandemic caused by H1N1 Swine-Origin Flu Virus (H1N1), in contrast to some other areas in the UK,1 there was only one H1N1-positive paediatric admission to Bristol Children's Hospital paediatric intensive care unit (PICU). Guidelines for the care of children admitted critically ill were published online by the Health Protection Agency (HPA) in the UK on 24 October 2009,2 advising that treatment should be started on clinical grounds, without waiting for results, in all children with fever and critical illness (defined in this study as needing PICU admission) since oseltamivir is most effective if given within 48 h …
Footnotes
-
Competing interests AF is chief and principal investigator in clinical trials funded by Roche, who manufacture Oseltamivir, and undertakes paid consultancy for Astra-Zeneca, who manufacture flu vaccine—all funds are paid to his employer.
-
Provenance and peer review Not commissioned; internally peer reviewed.